{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:49:10Z","timestamp":1762004950128},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-017-1541-7","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T09:35:24Z","timestamp":1516959324000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports"],"prefix":"10.1186","volume":"12","author":[{"given":"Dominick","family":"Amato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Anne","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,27]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00415-015-7889-y","volume":"262","author":"M Synofzik","year":"2015","unstructured":"Synofzik M, Harmuth F, Stampfer M, Muller Vom Hagen J, Schols L, Bauer P. NPC1 is enriched in unexplained early onset ataxia: a targeted high-throughput screening. J Neurol. 2015;262:2557\u201363.","journal-title":"J Neurol"},{"key":"1541_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA."},{"key":"1541_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151\u20136.","journal-title":"Hum Genet."},{"issue":"Suppl","key":"1541_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1651-2227.1986.tb14936.x","volume":"326","author":"A Erikson","year":"1986","unstructured":"Erikson A. Gaucher disease--Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand. 1986;326(Suppl):1\u201342.","journal-title":"Acta Paediatr Scand"},{"key":"1541_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis. 2010;33:339\u201346.","journal-title":"J Inherit Metab Dis."},{"key":"1541_CR6","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835\u201343.","journal-title":"Arch Intern Med."},{"key":"1541_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.mop.0000172702.33128.19","volume":"17","author":"GA Grabowski","year":"2005","unstructured":"Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr. 2005;17:519\u201324.","journal-title":"Curr Opin Pediatr."},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"22","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res. 2007;22:119\u201326.","journal-title":"J Bone Miner Res."},{"key":"1541_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10545-010-9071-0","volume":"33","author":"S Piran","year":"2010","unstructured":"Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis. 2010;33:271\u20139.","journal-title":"J Inherit Metab Dis."},{"key":"1541_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.bcmd.2011.04.005","volume":"47","author":"D Elstein","year":"2011","unstructured":"Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis. 2011;47:56\u201361.","journal-title":"Blood Cells Mol Dis."},{"key":"1541_CR11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","volume":"355","author":"T Cox","year":"2000","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355:1481\u20135.","journal-title":"Lancet."},{"key":"1541_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/bcmd.2002.0497","volume":"28","author":"R Heitner","year":"2002","unstructured":"Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002;28:127\u201333.","journal-title":"Blood Cells Mol Dis."},{"key":"1541_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757\u201366.","journal-title":"J Inherit Metab Dis."},{"key":"1541_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1750-1172-7-102","volume":"7","author":"TM Cox","year":"2012","unstructured":"Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD. Miglustat Maintenance Study Group. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis. 2012;7:102.","journal-title":"Orphanet J Rare Dis."},{"key":"1541_CR15","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","volume":"29","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Elstein D, Hrebicek M, Zimran A. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007;29:1645\u201354.","journal-title":"Clin Ther."},{"key":"1541_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcmd.2016.10.017","volume":"68","author":"P Giraldo","year":"2016","unstructured":"Giraldo P, Andrade-Campos M, Alfonso P, Irun P, Atutxa K, Acedo A, Barez A, Blanes M, Diaz-Morant V, Fernandez-Galan MA, Franco R, Gil-Cortes C, Giner V, Ibanez A, Latre P, Loyola I, Luno E, Hernandez-Martin R, Medrano-Engay B, Puerta J, Roig I, de la Serna J, Salamero O, Villalon L, Pocovi M. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project. Blood Cells Mol Dis. 2016;68:173\u20139.","journal-title":"Blood Cells Mol Dis."},{"key":"1541_CR17","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","volume":"110","author":"D Elstein","year":"2007","unstructured":"Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, Aerts JF, van Weely S, Zimran A. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood. 2007;110:2296\u2013301.","journal-title":"Blood."},{"key":"1541_CR18","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1528-1167.2007.01074.x","volume":"48","author":"JL Capablo","year":"2007","unstructured":"Capablo JL, Franco R, de Cabezon AS, Alfonso P, Pocovi M, Giraldo P. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase\/miglustat combination. Epilepsia. 2007;48:1406\u20138.","journal-title":"Epilepsia."},{"key":"1541_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","volume":"31","author":"J Cox-Brinkman","year":"2008","unstructured":"Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, Wijburg FA, Aerts JM. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745\u201352.","journal-title":"J Inherit Metab Dis."},{"key":"1541_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13256-016-1147-5","volume":"11","author":"F Ceravolo","year":"2017","unstructured":"Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report. J Med Case Rep. 2017;11:19.","journal-title":"J Med Case Rep."},{"key":"1541_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/08035320510028094","volume":"94","author":"JM Aerts","year":"2005","unstructured":"Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl. 2005;94:43\u20136.","journal-title":"Acta Paediatr Suppl."},{"key":"1541_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience. Radiology. 2003;229:554\u201361.","journal-title":"Radiology."},{"key":"1541_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ymgmr.2017.06.003","volume":"12","author":"CI Ha","year":"2017","unstructured":"Ha CI, DeArmey S, Cope H, Rairikar M, Kishnani PS. Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy. Mol Genet Metab Rep. 2017;12:82\u20134.","journal-title":"Mol Genet Metab Rep."},{"key":"1541_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/00498250601094543","volume":"37","author":"A Treiber","year":"2007","unstructured":"Treiber A, Morand O, Clozel M. The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007;37:298\u2013314.","journal-title":"Xenobiotica."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1541-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T19:17:19Z","timestamp":1548530239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1541-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1541-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2018,1,27]]},"assertion":[{"value":"26 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patients for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DA has received research and operating grants, honoraria for speaking, and travel funds from Actelion Pharmaceuticals, Genzyme Corporation, Protalix Biopharmaceuticals, and Shire Human Genetic Therapies. MAP has no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"19"}}